Abstract: The present invention relates to a novel trans-2-decenoic acid derivative or a pharmaceutically acceptable salt thereof, and a pharmaceutical agent containing the compound as an active ingredient. The trans-2-decenoic acid derivative or a pharmaceutically acceptable salt, which is the compound of the present invention, is specifically represented by the general formula (I): wherein X is a substituent such as a 1-pyrrolidyl, a 3-thiazolizyl, or a piperidino, and the compound is highly useful as a pharmaceutical agent, such as a prophylactic or therapeutic agent for a peripheral nerve disorder induced by administration of an anticancer agent, a prophylactic or therapeutic agent for neurodegenerative diseases or mental diseases such as dementia, Alzheimer's disease, Parkinson's disease, diabetic neuropathy, depression, glaucoma, or autistic disorder spectrum, a therapeutic or repairing agent for spinal cord injury, analgesics against various pain diseases, or the like.

Abstract: A novel gas separation membrane having excellent gas permeability and gas separation performance, particularly carbon dioxide (CO2) permeability and excellent separation performance of carbon dioxide to methane (CH4) is provided. Moreover, a novel gas separation membrane having excellent heat resistance, chemical resistance and strength etc. is preferably provided. A gas separation membrane comprising a resin comprising a branched polybenzoxazole has excellent gas permeability and gas separation performance, particularly excellent carbon dioxide (CO2) permeability and excellent separation performance of carbon dioxide to methane (CH4). The resin comprising a branched polybenzoxazole preferably has a cross-linked structure. Furthermore, the resin comprising a branched polybenzoxazole is preferably a hybrid with silica.

Abstract: The invention provides a liposome for delivery to the posterior segment of the eye, comprising (A) a phospholipid, (B) a charged substance, and/or (C) a membrane-reinforcing substance; the liposome having a rigidity that provides the liposome with cell membrane permeability, and having a mean particle diameter of 1 ?m or less; and a pharmaceutical composition for a disease in the posterior segment of an eye, comprising a drug encapsulated in the liposome. The liposome is delivered to the posterior segment of the eye by instillation, and is non-cytotoxic; and the pharmaceutical composition for a disease in the posterior segment of the eye comprises the liposome.

Abstract: An object of the present invention is to provide a novel trans-2-decenoic acid derivative or a pharmaceutically acceptable salt thereof and to provide a pharmaceutical agent which contains said compound as an active ingredient and has a highly safe neurotrophic factor-like activity or an alleviating action for side effect induced by administration of anti-cancer agents. The trans-2-decenoic acid derivative or a pharmaceutically acceptable salt thereof which is the compound of the present invention is specifically represented by the formula (1): (In the formula, Y is —O—, —NR— or —S—, R is hydrogen atom, alkyl group, dialkylaminoalkyl group or the like and W is a substituent such as dialkylaminoalkyl group) and has a quite high usefulness as a pharmaceutical agent such as a preventive or therapeutic agent for dementia, Alzheimer's disease, Parkinson's disease, depression, etc., a treating or repairing agent for spinal cord injury.

Abstract: A novel gas separation membrane having excellent gas permeability and gas separation performance, particularly carbon dioxide (CO2) permeability and excellent separation performance of carbon dioxide to methane (CH4) is provided. Moreover, a novel gas separation membrane having excellent heat resistance, chemical resistance and strength etc. is preferably provided. A gas separation membrane comprising a resin comprising a branched polybenzoxazole has excellent gas permeability and gas separation performance, particularly excellent carbon dioxide (CO2) permeability and excellent separation performance of carbon dioxide to methane (CH4). The resin comprising a branched polybenzoxazole preferably has a cross-linked structure. Furthermore, the resin comprising a branched polybenzoxazole is preferably a hybrid with silica.

Abstract: An object of the present invention is to provide a drug which is effective for prophylaxis or therapy of peripheral nerve disorder occurred as a side effect of the administration of anti-cancer agents. The present invention is to provide a drug containing an ester of C10 fatty acid as an active ingredient for prophylaxis or therapy of peripheral nerve disorder induced by administration of a drug containing at least one of anti-cancer agents. The drug of the present invention containing the compound as an active ingredient is highly useful as a drug for prophylaxis or therapy of peripheral nerve disorder induced by administration of anti-cancer agents.

Abstract: An object of the present invention is to provide an analgesic effective in a prophylactic or a therapy for various pain diseases. The present invention is to provide an analgesic containing an ester of C10 fatty acid as an active ingredient. The analgesic of the present invention containing the compound as an active ingredient is highly useful as a prophylactic or therapeutic agent for various pain diseases such as the pain caused by osteoarthritis (e.g., knee osteoarthritis and hip osteoarthritis) or by demyelinating diseases such as multiple sclerosis or Guillain-Bareé syndrome.

Abstract: A method for preventing or treating a nervous disorder can include administrating to a person in need of such prevention or treatment a pharmaceutical preparation comprising, as an active ingredient, an ester of a decenoic acid. The ester of the decenoic acid can be selected from the group consisting of trans-2-decenoic acid ethyl ester, trans-2-decenoic acid methyl ester, trans-2-decenoic acid-2-decenyl ester, trans-2-decenoic acid cyclohexyl ester, trans-2-decenoic acid octyl ester, trans-2-decenoic acid isopropyl ester, trans-3-decenoic acid methyl ester, trans-3-decenoic acid ethyl ester, trans-9-decenoic acid methyl ester, and trans-9-decenoic acid ethyl ester.

Abstract: An object of the present invention is to provide a novel trans-2-decenoic acid derivative or a pharmaceutically acceptable salt thereof and to provide a pharmaceutical agent which contains said compound as an active ingredient and has a highly safe neurotrophic factor-like activity or an alleviating action for side effect induced by administration of anti-cancer agents. The trans-2-decenoic acid derivative or a pharmaceutically acceptable salt thereof which is the compound of the present invention is specifically represented by the formula (1): (In the formula, Y is —O—, —NR— or —S—, R is hydrogen atom, alkyl group, dialkylaminoalkyl group or the like and W is a substituent such as dialkylaminoalkyl group) and has a quite high usefulness as a pharmaceutical agent such as a preventive or therapeutic agent for dementia, Alzheimer's disease, Parkinson's disease, depression, etc., a treating or repairing agent for spinal cord injury.

Abstract: The present invention provides a pharmaceutical agent having high safety and a neurotrophic factor-like activity, which contains, as an active ingredient, any one compound included in fatty acids each having 8 carbon atoms (C8) or having 10 carbon atoms (C10) to 12 carbon atoms (C12) or fatty acid esters thereof, such as 3,7-dimethyloctanoic acid ethyl ester, geranic acid ethyl ester, and the like, each of which has 8 carbon atoms (C8), decanoic acid methyl ester, trans-2-decenoic acid, trans-2-decenoic acid methyl ester, trans-2-decenoic acid ethyl ester, trans-2-decenoic acid-2-decenyl ester, trans-2-decenoic acid cyclohexyl ester, trans-2-decenoic acid isopropyl ester, trans-3-decenoic acid methyl ester, trans-9-decenoic acid methyl ester, and the like, each of which has 10 carbon atoms (C10), trans-10-undecenoic acid methyl ester, trans-10-undecenoic acid ethyl ester, and the like, each of which has 11 carbon atoms (C11), and dodecanoic acid, and the like, each of which has 12 carbon atoms (C12), or salts

Abstract: A novel ruthenium complex which is a highly efficient catalyst useful for the production of optically active 3-quinuclidinols, and a process for production of optically active 3-quinuclidinols using the ruthenium complex as a catalyst, where the optically active 3-quinuclidinols are useful as an optically active, physiologically active compound utilized in medicines and agrichemicals or as a synthetic intermediate such as a liquid crystal material.

Abstract: Provided is a method of preparing a proliferation-regulated recombinant adenoviral vector effectively, comprising preparing a proliferation-regulated vector plasmid by preparing a restriction enzyme-recognizing sequence in a vector plasmid having a proliferation-regulating unit and having an E1A region, a protein-coding region in a E1B region, a poly(A) signal sequence, and a recombinase-recognizing sequence in that order from upstream, by deleting an endogenous promoter in the E1A region or an endogenous promoter regulating expression of the protein-coding gene in one protein-coding region of the E1B region thereof and inserting the restriction enzyme-recognizing sequences in the deficient site, and introducing a promoter expressing specifically in a target organ in the restriction enzyme-recognizing sequence in the restriction enzyme-recognizing sequence; and additionally, integrating the proliferation-regulated vector plasmid into a vector plasmid having a adenoviral genome prepared by deleting the E1 regi

Abstract: Means for easily determining the grade of malignancy of cancer cells. The amount of ATBF1 in the whole cell structure of test cancer cells separated from a living organism is detected, and on the basis of detection results, the grade of malignancy of test cancer cells is judged. Alternatively, the amount of ATBF1 in the nuclei of test cancer cells separated from a living organism is detected, and on the basis of detection results, the grade of malignancy of test cancer cells is judged. Still alternatively, the amount of ATBF1 in the cytoplasms of test cancer cells separated from a living organism is detected, and on the basis of detection results, the grade of malignancy of test cancer cells is judged.

Abstract: The invention provides a liposome for delivery to the posterior segment of the eye, comprising (A) a phospholipid, (B) a charged substance, and/or (C) a membrane-reinforcing substance; the liposome having a rigidity that provides the liposome with cell membrane permeability, and having a mean particle diameter of 1 ?m or less; and a pharmaceutical composition for a disease in the posterior segment of an eye, comprising a drug encapsulated in the liposome. The liposome is delivered to the posterior segment of the eye by instillation, and is non-cytotoxic; and the pharmaceutical composition for a disease in the posterior segment of the eye comprises the liposome.

Abstract: A drug for preventing or treating heart diseases which comprises an expression vector containing CD9 gene as the active ingredient. In the present invention, the term “heart diseases” means diseases causative of heart failure, ischemic heart diseases, cardiomyopathy, hypertensive heart diseases, valvular disease, congenital heart diseases, mayocarditis, arrhythmia and diseases associated with cardiac hypertrophy and/or tachycardia. In the present invention, the expression vector is a viral vector or a non-viral vector. A method for preventing or treating heart diseases which comprises expressing the CD9 gene in the heart. In the present invention, the prevention or the treatment is carried out by a gene therapy of transferring the CD9 gene. In the gene therapy, use is made of a drug comprising an expression vector containing the CD9 gene as the active ingredient.

Abstract: The histamine detection method of the invention includes: a reaction step of causing a sample solution possibly containing histamine to react with 2,3-naphathalene dicarboxylaldehyde at PH of less than 10; and a detection step of detecting histamine based on a color change in the reaction step. The arrangement of this histamine detection method ensures the good color development in a visible region and thus enables easy and quick detection of histamine.

Abstract: It is intended to provide a means of diagnosing myocardial infarction which shows a high accuracy and a high predictability. The risk of myocardial infarction is diagnosed by a method comprising the following steps: (i) the step of analyzing 2 or more polymorphisms among 10 gene polymorphisms or 5 gene polymorphisms proved as relating to myocardial infarction; (ii) the step of determining the genotype of a nucleic acid sample based on the polymorphism data obtained in the above step; and (iii) the step of determining the genetic risk of myocardial infarction from the genotype thus obtained.

Abstract: It is intended to provide a transgenic nonhuman mammal well representing the pathologic conditions of human rheumatoid arthritis. A transgenic nonhuman mammal is obtained by transferring a foreign DNA, wherein a DNA selected from the group consisting of an MHC class II transcriptional activator gene, the activity domain of an MHC class II transcriptional activator gene and a variant of an MHC class II transcriptional activator gene is provided under the control of a type II collagen promoter, into a cell at the early stage of development.

Abstract: It is intended to provide a model animal faithfully reproducing the pathogenic conditions of spinal and bulbar muscular atrophy, a method of screening a remedy for polyglutamine disease using the same, and a remedy for spinal and bulbar muscular atrophy. Namely, a nonhuman animal having the following characteristics (1) to (5) in its conditions or pathological findings: (1) showing progressive myoatrophy; (2) showing lowering in muscular power; (3) in immunostaining with the use of an anti-polyglutamine antibody, showing nuclear diffuse staining and nuclear inclusions; (4) in immunostaining with the use of an anti-androgen receptor antibody, showing nuclear diffuse staining and nuclear inclusions; and (5) showing a neurogenic change. A remedy for polyglutamine disease is screened by administering a test substance to this nonhuman animal and examining changes in its conditions or pathological findings.

Abstract: An optical tactile sensor has a touch pad and a CCD camera for imaging behavior of the touch pad. A CPU processes image information from the CCD camera, extracts information on the size, shape, and center of gravity of a contact region, and extracts information on the size of a fixation region. The CPU obtains a normal force from the size of the contact region, obtains a tangential force from the shape of the contact region and the center of gravity of the contact region, and obtains a friction coefficient from the ratio of the size of the fixation region to the size of the contact region.